-
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its anti-PD-1 drug Keytruda (pembrolizumab) has successfully met the primary endpoint of statistically significant and clinically meaningful improvement in overall survival (OS) in patients with resectable non-small cell lung cancer (NSCLC). The trial evaluated Keytruda as…
-
Bayer AG Plans Continued Investment in China Amidst Global Challenges
•
Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as stated by Matthias Berninger, Executive Vice-President of Public Affairs, Science, Sustainability, and HSE at Bayer. Berninger’s comments came in an interview with China Daily in anticipation of the China International Import Expo, scheduled for November…
-
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
•
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global study evaluating the impact of the GLP-1 receptor agonist Ozempic (semaglutide) on the progression of renal impairment in individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD). The decision was recommended by an…
-
BMS Expands CAR-T Collaboration with Cellares on Automation Tech
•
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a technology transfer agreement with US-based Cellares, a company specializing in automated manufacturing platforms for cell therapies. This marks the second collaboration between the two entities, focusing on the production of an unnamed CAR-T cell therapy. The agreement highlights BMS’s commitment to…
-
Henlius Pharmaceutical Secures GMP Compliance for PD-1 Inhibitor Serplulimab in Indonesia
•
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced that its partner, PT Kalbe Genexine Biologics (KGbio), through its subsidiary PT Kalbio Global Medika, has received a GMP inspection completion letter from the Badan Pengawas Obat dan Makanan (BPOM), a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) in Indonesia.…
-
Medilink Therapeutics Enters Global Licensing Agreement with BioNTech for HER3-Targeted Antibody Drug Conjugates
•
Suzhou-based Medilink Therapeutics has announced a strategic cooperation and global licensing agreement with Germany-headquartered BioNTech SE (NASDAQ: BNTX). Under this partnership, the two companies will collaborate to develop next-generation antibody drug conjugates (ADCs) targeting the human epidermal growth factor receptor 3 (HER3). Leveraging TMALIN Technology for Enhanced Efficacy The ADC…
-
Jiangsu BioPerfectus Secures NMPA Approval for Norovirus Nucleic Acid Detection Kit
•
China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic (IVD) products, has announced that it has received medical device approval from the National Medical Products Administration (NMPA) for its Norovirus nucleic acid detection kit, utilizing the fluorescence PCR method. Innovative Detection of Norovirus The…
-
Kintor Pharmaceutical Secures NMPA Approval for Phase II Study of GT1708F in Idiopathic Pulmonary Fibrosis
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical study for its Hedgehog/SMO inhibitor, GT1708F, targeting idiopathic pulmonary fibrosis (IPF). Understanding the Role of Hedgehog Signaling in IPF Recent research has highlighted the…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis Novo Nordisk NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
